Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

pharma 1 > Anticancer drugs > Flashcards

Anticancer drugs Flashcards

1
Q

Alemtuzumab

TARGET and ADVERSEEFFECT S

A

CD52
increase risk of infections and
autoimmunity (eg, Immune thrombocytopenia(ITP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CD52
increase risk of infections and
autoimmunity (eg, Immune thrombocytopenia(ITP)

A

Alemtuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bevacizumab

TARGET and ADVERSEEFFECT S

A

VEGF (inhibits blood vessel
formation)

Hemorrhage, blood clots,
impaired wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

VEGF (inhibits blood vessel
formation)

Hemorrhage, blood clots,
impaired wound healing

A

Bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cetuximab,panitumumab

A

EGFR
Rash, elevated LFTs, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

EGFR
Rash, elevated LFTs, diarrhea

monoclonal antibodie

A

Cetuximab,panitumumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CD20
Non-Hodgkin lymphoma,
CLL, rheumatoid arthritis,
ITP, TTP, AIHA, multiple
sclerosis

A

Rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Rituximab

target and clinical use

A

CD20

Non-Hodgkin lymphoma,
CLL, rheumatoid arthritis,
ITP, TTP, AIHA, multiple
sclerosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Trastuzumab

target and adverseeffect

A

HER2

(“trust HER”) Dilated cardiomyopathy (often reversible)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HER2
​
(“trust HER”) Dilated cardiomyopathy (often reversible)

A

Trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pembrolizumab,
nivolumab,
cemiplimab

A

PD-1
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis, endocrinopathies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PD-1
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis, endocrinopathies)

A

Pembrolizumab,
nivolumab,
cemiplimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Atezolizumab,
durvalumab,
avelumab

A

PD-L1
increase risk of autoimmunity (eg,
dermatitis, enterocolitis,
hepatitis, pneumonitis,
endocrinopathies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ipilimumab

A

CTLA-4
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis,endocrinopathies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CTLA-4
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis,endocrinopathies)

A

Ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ALK
Edema, rash, diarrhea

A

Alectinib,crizotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Alectinib,crizotinib

A

ALK
Edema, rash, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

EGFR
Rash, diarrhea

A

Erlotinib, gefitinib,
afatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Erlotinib, gefitinib,afatinib

A

EGFR
Rash, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

BCR-ABL
Myelosuppression, increase LFTs,
edema, myalgias

A

Imatinib, dasatinib,
nilotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Imatinib, dasatinib,
nilotinib

A

BCR-ABL
Myelosuppression, increase LFTs,
edema, myalgias

22
Q

JAK1/2 Bruises, increase LFTs

A

Ruxolitinib

23
Q

Ruxolitinib

A

JAK1/2 Bruises, increase LFTs

24
Q

Proteasome (induce
arrest at G2-M phase via
accumulation of abnormal
proteins leading to apoptosis).

Peripheral neuropathy, herpes
zoster reactivation (decrease T-cell
activation leading to deacrese cell-mediated
immunity)

A

Bortezomib, ixazomib,
carfilzomib

25
Bortezomib, ixazomib, carfilzomib
Proteasome (induce arrest at G2-M phase via accumulation of abnormal proteins leading to apoptosis). Peripheral neuropathy, herpes zoster reactivation (decrease T-cell activation leading to deacrese cell-mediated immunity)
26
BRAF Rash, fatigue, nausea, diarrhea
Vemurafenib, encorafenib, dabrafenib
27
Vemurafenib, encorafenib, dabrafenib
BRAF Rash, fatigue, nausea, diarrhea
28
Cyclin-dependent kinase 4/6 (induces arrest at G1-S phase leading to apoptosis) Myelosuppression, pneumonitis
Palbociclib
29
Poly(ADP-ribose) polymerase (decrease DNA repair) Myelosuppression, edema, diarrhea
Olaparib
30
Olaparib
Poly(ADP-ribose) polymerase (decrease DNA repair) ​ Myelosuppression, edema, diarrhea
31
Free radical scavenger Nephrotoxicity from platinum compounds | MECHAN ISM , CL INICAL USE
Amifostine
32
Iron chelator Cardiotoxicity from anthracyclines | MECHAN ISM , CL INICAL USE
Dexrazoxane
33
Tetrahydrofolate precursor Myelosuppression from methotrexate (leucovorin “rescue”); also enhances the effects of 5-FU | MECHAN ISM , CL INICAL USE
Leucovorin (folinic acid)
34
-Sulfhydryl compound that binds acrolein (toxic metabolite of cyclophosphamide/ifosfamide) -Hemorrhagic cystitis from cyclophosphamide/ ifosfamide | MECHAN ISM , CL INICAL USE
Mesna
35
- Recombinant uricase that catalyzes metabolism of uric acid to allantoin -Tumor lysis syndrome | MECHAN ISM , CL INICAL USE
Rasburicase
36
Amifostine | MECHAN ISM , CL INICAL USE
Free radical scavenger Nephrotoxicity from platinum compounds
37
Dexrazoxane | MECHAN ISM , CL INICAL USE
Iron chelator Cardiotoxicity from anthracyclines
38
Leucovorin (folinic acid) | MECHAN ISM , CL INICAL USE
Tetrahydrofolate precursor Myelosuppression from methotrexate (leucovorin “rescue”); also enhances the effects of 5-FU
39
Mesna | MECHAN ISM , CL INICAL USE
-Sulfhydryl compound that binds acrolein (toxic metabolite of cyclophosphamide/ifosfamide) -Hemorrhagic cystitis from cyclophosphamide/ ifosfamide
40
Rasburicase | MECHAN ISM , CL INICAL USE
-Recombinant uricase that catalyzes metabolism of uric acid to allantoin -Tumor lysis syndrome
41
5-HT3 receptor antagonists Acute nausea and vomiting | MECHAN ISM , CL INICAL USE
Ondansetron, granisetron
42
D2 receptor antagonists Acute nausea and vomiting
Prochlorperazine, metoclopramide
43
NK1 receptor antagonists Delayed nausea and vomiting (>24 hr after chemotherapy)
Aprepitant,fosaprepitant
44
Recombinant G(M)-CSF Neutropenia
Filgrastim, sargramostim
45
Recombinant erythropoietin Anemia
Epoetin alfa
46
Ondansetron, granisetron | MECHAN ISM , CL INICAL USE
5-HT3 receptor antagonists Acute nausea and vomiting
47
Prochlorperazine, metoclopramide | MECHAN ISM , CL INICAL USE
D2 receptor antagonists Acute nausea and vomiting
48
Aprepitant, fosaprepitant
NK1receptor antagonists Delayed nausea and vomiting
49
Filgrastim, sargramostim
Recombinant G(M)-CSF Neutropenia
50
Epoetin alfa
Recombinant erythropoietin Anemia

pharma 1 (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions